Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Artigo Acesso aberto Revisado por pares

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

2013; Elsevier BV; Volume: 8; Issue: 3 Linguagem: Inglês

10.1097/jto.0b013e31827e1f83

ISSN

1556-1380

Autores

Helena A. Yu, Camelia S. Sima, James Huang, Stephen B. Solomon, Andreas Rimner, Paul K. Paik, M. Catherine Pietanza, Christopher G. Azzoli, Naiyer A. Rizvi, Lee M. Krug, Vincent A. Miller, Mark G. Kris, Gregory J. Riely,

Tópico(s)

Lung Cancer Diagnosis and Treatment

Resumo

Development of acquired resistance limits the utility of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung cancers. There are no accepted targeted therapies for use after acquired resistance develops. Metastasectomy is used in other cancers to manage oligometastatic disease. We hypothesized that local therapy is associated with improved outcomes in patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI.

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors